Geoff Meacham
Stock Analyst at Citigroup
(4.43)
# 362
Out of 5,182 analysts
297
Total ratings
60.85%
Success rate
14.88%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Buy | $156 → $165 | $127.75 | +29.16% | 10 | Apr 13, 2026 | |
| BIIB Biogen | Maintains: Neutral | $215 → $190 | $180.67 | +5.16% | 20 | Apr 13, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Buy | $14 → $16 | $9.13 | +75.25% | 2 | Mar 27, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $95 → $125 | $86.49 | +44.53% | 3 | Mar 24, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $120 → $125 | $110.23 | +13.40% | 12 | Mar 20, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $115 → $125 | $98.51 | +26.89% | 5 | Mar 19, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $145 → $130 | $102.06 | +27.38% | 3 | Mar 11, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $97 → $85 | $53.81 | +57.98% | 4 | Mar 11, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $575 → $585 | $426.01 | +37.32% | 7 | Mar 10, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $55 → $58 | $46.29 | +25.30% | 2 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $120 | $86.68 | +38.44% | 8 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $100.10 | -15.08% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $110 → $115 | $115.07 | -0.06% | 2 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $16.88 | +12.56% | 6 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $64 | $57.78 | +10.76% | 9 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $315 → $345 | $340.18 | +1.42% | 14 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $230 | $197.38 | +16.53% | 22 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $49.65 | +0.70% | 4 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $14.12 | +254.11% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $49 | $15.23 | +221.73% | 3 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $26 | $26.79 | -2.95% | 7 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $2.52 | +217.46% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $75 | $69.22 | +8.35% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $700 | $744.44 | -5.97% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $28 | $48.70 | -42.51% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $30.45 | +64.20% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $43.61 | +14.65% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $50.99 | +82.39% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $10.64 | +31.58% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $74.52 | -27.54% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $8.07 | -25.65% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $2.22 | -54.95% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $1.09 | +266.97% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $868.27 | +26.69% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $22.77 | -12.17% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $36.92 | -16.03% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $225.34 | -24.56% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $0.89 | +1,810.33% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.17 | +1,951.28% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $14.74 | -72.86% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $19.15 | +46.21% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.25 | +1,411.11% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $1.91 | +1,732.46% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.44 | +2,816.67% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.21 | +9,423.81% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $7.51 | +19.84% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $8.62 | +596.06% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $28.56 | -19.47% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $95.72 | -14.33% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $566.99 | -83.24% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $20.39 | +292.35% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $128.04 | +5.44% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.79 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $4.04 | +395.05% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $9.59 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $308.51 | -48.79% | 5 | Nov 8, 2017 |
Gilead Sciences
Apr 13, 2026
Maintains: Buy
Price Target: $156 → $165
Current: $127.75
Upside: +29.16%
Biogen
Apr 13, 2026
Maintains: Neutral
Price Target: $215 → $190
Current: $180.67
Upside: +5.16%
MeiraGTx Holdings
Mar 27, 2026
Maintains: Buy
Price Target: $14 → $16
Current: $9.13
Upside: +75.25%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $95 → $125
Current: $86.49
Upside: +44.53%
Merck & Co.
Mar 20, 2026
Maintains: Neutral
Price Target: $120 → $125
Current: $110.23
Upside: +13.40%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $115 → $125
Current: $98.51
Upside: +26.89%
BioNTech SE
Mar 11, 2026
Maintains: Buy
Price Target: $145 → $130
Current: $102.06
Upside: +27.38%
BioMarin Pharmaceutical
Mar 11, 2026
Maintains: Buy
Price Target: $97 → $85
Current: $53.81
Upside: +57.98%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $575 → $585
Current: $426.01
Upside: +37.32%
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $55 → $58
Current: $46.29
Upside: +25.30%
Mar 2, 2026
Maintains: Buy
Price Target: $110 → $120
Current: $86.68
Upside: +38.44%
Mar 2, 2026
Initiates: Buy
Price Target: $85
Current: $100.10
Upside: -15.08%
Feb 24, 2026
Downgrades: Neutral
Price Target: $110 → $115
Current: $115.07
Upside: -0.06%
Feb 20, 2026
Maintains: Buy
Price Target: $15 → $19
Current: $16.88
Upside: +12.56%
Feb 6, 2026
Maintains: Neutral
Price Target: $60 → $64
Current: $57.78
Upside: +10.76%
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $345
Current: $340.18
Upside: +1.42%
Jan 27, 2026
Maintains: Neutral
Price Target: $235 → $230
Current: $197.38
Upside: +16.53%
Jan 27, 2026
Maintains: Buy
Price Target: $48 → $50
Current: $49.65
Upside: +0.70%
Jan 9, 2026
Initiates: Buy
Price Target: $50
Current: $14.12
Upside: +254.11%
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $15.23
Upside: +221.73%
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $26.79
Upside: -2.95%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.52
Upside: +217.46%
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $69.22
Upside: +8.35%
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $744.44
Upside: -5.97%
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $48.70
Upside: -42.51%
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $30.45
Upside: +64.20%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $43.61
Upside: +14.65%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $50.99
Upside: +82.39%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $10.64
Upside: +31.58%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $74.52
Upside: -27.54%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $8.07
Upside: -25.65%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $2.22
Upside: -54.95%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $1.09
Upside: +266.97%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $868.27
Upside: +26.69%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $22.77
Upside: -12.17%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $36.92
Upside: -16.03%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $225.34
Upside: -24.56%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $0.89
Upside: +1,810.33%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.17
Upside: +1,951.28%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $14.74
Upside: -72.86%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $19.15
Upside: +46.21%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $2.25
Upside: +1,411.11%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $1.91
Upside: +1,732.46%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.44
Upside: +2,816.67%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.21
Upside: +9,423.81%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $7.51
Upside: +19.84%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $8.62
Upside: +596.06%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $28.56
Upside: -19.47%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $95.72
Upside: -14.33%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $566.99
Upside: -83.24%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $20.39
Upside: +292.35%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $128.04
Upside: +5.44%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $10.79
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $4.04
Upside: +395.05%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.59
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $308.51
Upside: -48.79%